IU researchers identify proteins fueling rare childhood leukemia, revealing new treatment strategy
Indiana University School of Medicine cancer researchers have identified a potential way to use existing, accessible drugs to combat juvenile myelomonocytic leukemia (JMML) by targeting a specific inflammatory pathway. Read more: https://firstwordpharma.com/story/7627533
Jun 24
Therapy Shows Promise for Rare Leukemia in Children
Kinase inhibitor trametinib may spare patients from intensive treatments, such as stem cell transplant, for an aggressive form of blood...
Jul 3, 2024
Trametinib Shows Promise for Children with Relapsed or Refractory JMML
The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile...
Jun 17, 2024
DNA sequencing reveals clonal evolution of tumor in childhood leukemia
Researchers at the RUDN Laboratory of Biology of Single Cells have studied the possibilities of DNA sequencing at the level of individual...
Dec 14, 2023
FDA Approves Vidaza for Rare Pediatric Blood Cancer
The Food and Drug Administration (FDA) approved Vidaza (azacytidine) for the treatment of pediatric patients with newly diagnosed...
May 24, 2022
How a Powerful Genetic Test Matched An Infant’s Cancer to a Life-Saving Therapy
Doctors have successfully treated an infant with a rare childhood leukemia using a targeted therapy approved for adults with inoperable...
Sep 13, 2019
Childhood Leukemia Outcomes May Be Informed by DNA Methylation Patterns
Two studies by independent research teams have identified epigenetic subgroups in children with a rare pediatric leukemia called juvenile...
Dec 20, 2017
UAMS Cancer Researchers Publish Findings on Rare Childhood Leukemia
New findings on juvenile myelomonocytic leukemia (JMML) by researchers at the University of Arkansas for Medical Sciences (UAMS) and...
Oct 20, 2015